A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chęć udziału w badaniu i podpisanie zgody.
- •Wiek od 18 do 75 lat, niezależnie od płci.
- •Potwierdzony histopatologicznie nowotwór z grupy limfocytów B (np. chłoniak), który nie zareagował na dostępne leczenie i nie ma innych opcji terapeutycznych.
- •Potwierdzony histopatologicznie nowotwór szpiku (np. ostra białaczka szpikowa, zespoły mielodysplastyczne), który nawrócił lub jest oporny na leczenie.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Beijing Cancer Hospital
Beijing, China
Sun Yat-sen University Cancer Center
Guangdong, China
Affiliated Hospital of Hebei University
Hebei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei, China
Trial contact
Jun Zhu, MD
Yuqin Song, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.